CuraTeQ Biologics

  • Biosimilars Pipeline
About CuraTeQ Biologics

CuraTeQ Biologics is a biopharmaceutical company based out of Hyderabad, India. CuraTeQ has a development pipeline of 14 biosimilars, of which, three products have been filed with EMA, one product has been filed with MHRA, and four more products are in global phase 3 clinical trials.

  • Dazublys™ our biosimilar referencing Trastuzumab, has received recommendation for marketing authorization in India, and is also filed with EMA.
  • Auro Peptides, our synthetic peptides manufacturing arm, has filed 14 DMFs with US FDA that have contributed to 6 ANDA approvals.

  • IN
  • 2024
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Generics/Biosimilars Manufacturer
Primary activities
Biopharmaceutical
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
Contact info
  • CuraTeQ Biologics, , Survey No. 77 & 78, Indrakaran Village, Kandi Mandal, Sangareddy Distr, 502329, Hyderabad, Telangana, India
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

Products from CuraTeQ Biologics (2)

  • Biosimilars Portfolio

    Product Biosimilars Portfolio

    • Pegfilgrastim (Filed with EMA) • Filgrastim (Filed with EMA) • Trastuzumab (Filed with EMA, MHRA, Received recommendation for marketing authorization in India) • Bevacizumab (Filed with MHRA) • Omalizumab (Global PhIII ongoing) • Denosumab (Global PhIII ongoing) • Ranibizumab (Global PhIII ongoing...
  • Synthetic Peptide APIs Portfolio

    Product Synthetic Peptide APIs Portfolio

    • Vasopressin (US DMF Approved) • Icatibant acetate (US DMF Approved) • Leuprolide acetate (US DMF Approved) • Linaclotide (US DMF Approved) • Etelcalcetide (US DMF Approved) • Desmopressin (US DMF Approved) • Calcitonin salmon (US DMF Filed) • Ganirelix acetate (US DMF Filed) • Degarelix (US DMF ...

CuraTeQ Biologics Resources (1)